| 62.05 -0.02 (-0.03%) | 07-29 10:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 73.64 | 1-year : | 86.01 |
| Resists | First : | 63.04 | Second : | 73.64 |
| Pivot price | 59.66  |
|||
| Supports | First : | 58.94 |
Second : | 56.4 |
| MAs | MA(5) : | 60.54 |
MA(20) : | 59.53 |
| MA(100) : | 56.11 |
MA(250) : | 56.26 |
|
| MACD | MACD : | 1 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 82.5 |
D(3) : | 72.5 |
| RSI | RSI(14): 68 |
|||
| 52-week | High : | 66.27 | Low : | 49.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMRN ] has closed above the upper band by 8.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 17.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.06 - 63.28 | 63.28 - 63.48 |
| Low: | 60.3 - 60.58 | 60.58 - 60.84 |
| Close: | 61.62 - 62.02 | 62.02 - 62.38 |
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human tripeptidyl peptidase 1 used in treating ceroid lipofuscinosis type 2, a variant of Batten disease; Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a refined protein mirroring the naturally occurring human enzyme alpha-L-iduronidase. Beyond its established products, BioMarin has a robust development pipeline. This includes valoctocogene roxaparvovec, an adeno-associated virus vector undergoing Phase III clinical trials for severe hemophilia A. Additionally, BMN 307, an AAV5-mediated gene therapy, is in Phase 1/2 trials, aiming to normalize blood phenylalanine levels in PKU patients, while BMN 255 is also in Phase 1/2 trials for primary hyperoxaluria. Its clientele spans specialty pharmacies, hospitals, international government health bodies, and a network of distributors and pharmaceutical wholesalers. These services reach patients and healthcare providers across the United States, Europe, Latin America, and other global markets. BioMarin maintains strategic licensing and collaborative alliances with partners such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. Established in 1996, the company's corporate headquarters are located in San Rafael, California.
Mon, 27 Jul 2026
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Mon, 27 Jul 2026
BioMarin Pharmaceutical (NASDAQ:BMRN): A Value Stock with Strong Fundamentals - ChartMill
Mon, 27 Jul 2026
BioMarin Pharmaceutical Inc (BMRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sat, 25 Jul 2026
BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings - ChartMill
Fri, 24 Jul 2026
BioMarin Pharmaceutical (BMRN) On FDA Acceptance For VOXZOGO And The Valuation Case - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 193 (M) |
| Shares Float | 192 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 102.3 (%) |
| Shares Short | 14,320 (K) |
| Shares Short P.Month | 12,520 (K) |
| EPS | 1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 32.13 |
| Profit Margin | 8.2 % |
| Operating Margin | 18 % |
| Return on Assets (ttm) | 4.4 % |
| Return on Equity (ttm) | 4.4 % |
| Qtrly Rev. Growth | 2.7 % |
| Gross Profit (p.s.) | 8.58 |
| Sales Per Share | 16.76 |
| EBITDA (p.s.) | 3.26 |
| Qtrly Earnings Growth | -43.1 % |
| Operating Cash Flow | 874 (M) |
| Levered Free Cash Flow | 459 (M) |
| PE Ratio | 44.75 |
| PEG Ratio | 0.7 |
| Price to Book value | 1.93 |
| Price to Sales | 3.71 |
| Price to Cash Flow | 13.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|